Joincare Pharmaceutical Group Industry (600380.SH): TSLP monoclonal antibody receives approval for new indication to conduct drug clinical trials.

Joincare Pharmaceutical Group Industry (600380.SH) announced that the company has recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (referred to as the NMPA) regarding the addition of the indication of "Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)" for the company's TSLP monoclonal antibody. JKN2401 injection (referred to as the product) is an innovative biological agent targeting thymic stromal lymphopoietin (TSLP), intended for the treatment of respiratory system and airway inflammation-related diseases. TSLP is one of the key cytokines of epithelial origin, located upstream in multiple inflammatory cascades, playing an important role in the occurrence and development of airway inflammation and diseases such as chronic rhinosinusitis with nasal polyps. By targeting and blocking the TSLP pathway, the product is expected to intervene in the disease process from the upstream inflammatory response, thereby improving related symptoms and reducing the risk of disease recurrence.